ADA2 and chronic myelogenous leukemia, BCR-ABL1 positive: Other authors have tested breakpoint-derived peptide vaccines in CML, attempting to increase immunogenicity by using synthetic structures (“heteroclitic” peptides) [22,23] or by linking P210 breakpoint peptides to known immunogenic PAN DR epitope [24].